Keep knowledgeable with free updates
Merely signal as much as the Prescribed drugs sector myFT Digest — delivered on to your inbox.
Drugmaker Eli Lilly has received US regulatory approval to promote a weight-loss drug in capsule type, establishing a combat with rival Novo Nordisk out there for oral weight problems medicines.
The approval for Lilly’s capsule, known as Foundayo, was broadly anticipated by traders to be introduced this month. Nonetheless, the drugmaker’s shares rose 4 per cent after it introduced the US Meals and Drug Administration approval. Indianapolis-based Lilly mentioned docs can begin writing prescriptions for the capsule instantly and shipments to sufferers will start on April 6.
Lilly is the world chief in gross sales of weight-loss and diabetes medication, with about 1.5mn prescriptions written within the US via mid-March for its injectable therapies Zepbound, Mounjaro and Trulicity, in response to information from Iqvia.
However Novo Nordisk has gained floor on Lilly with its weight problems capsule Wegovy, which launched within the US in early January. Analysts and trade members have mentioned Novo’s capsule has loved report gross sales development for a brand new drug within the pharmaceutical trade.
Novo’s diabetes and weight-loss prescriptions totalled 957,000 within the US in mid-March, Iqvia information reveals. Novo’s US-listed shares dipped 1 per cent on Wednesday.
Talking to reporters on Tuesday, Lilly’s chief government Dave Ricks mentioned the capsule had been submitted for regulatory approval in additional than 40 international locations. The Gulf international locations “have a tendency to maneuver slightly faster” with drug approvals and may very well be among the many first international locations outdoors the US to approve the capsule, he mentioned.
The prices of weight-loss and weight problems therapies have been falling. Lilly and Novo have already lowered costs for weight-loss medication to compete for market share and reply to President Donald Trump’s demand for cheaper medicines. They may face renewed strain when extra opponents enter the market in coming years. Pfizer, for instance, final yr acquired Metsera, an weight problems start-up which is predicted to launch a weight-loss shot in 2028.
The capsule approval “marks a significant optimistic milestone within the evolution of Lilly’s weight problems [and] metabolic franchise”, Evan Seigerman, an analyst with BMO Capital Markets, mentioned in a report. “With approval in hand, Lilly will look to instantly compete with Novo’s oral Wegovy capsule.”
Lilly’s new capsule is totally different from Novo’s in that folks can take it with meals. Novo’s capsule is meant to be taken half-hour earlier than consuming.
However Novo’s capsule was discovered to assist individuals shed extra weight. The corporate has mentioned sufferers have misplaced a median of 17 per cent of their physique weight in the event that they follow the therapy. Lilly has mentioned individuals misplaced a median of 12.4 per cent on Foundayo, on the decrease finish of the market’s expectations.
Buyers could be watching carefully to see if individuals want one choice over the opposite, Siegerman mentioned.
Lilly mentioned the capsule would value $149 a month for the bottom dose, and folks with insurance coverage protection may get it for as little as $25 a month. The capsule would even be obtainable via sure Medicare plans for $50 a month, starting on July 1. Medicare is the US insurance coverage programme for senior residents.
After Lilly’s announcement, Novo mentioned that any stories its rival’s capsule was more practical “are inaccurate and deceptive”.
“There is no such thing as a head-to-head trial evaluating the efficacy of [Foundayo] and Wegovy capsule,” mentioned Jamey Millar, government vice-president of Novo’s US operations. The Wegovy capsule “has demonstrated a magnitude of weight reduction” unmatched by opponents, he mentioned.
